Bayer sweetens takeover bid again

(iStock)
(iStock)

Chicago - Bayer sweetened its takeover bid for Monsanto Company a second time and said the two are in advanced talks as the German chemical company seeks to become the world’s largest producer of seeds and pesticides.

Bayer would be prepared to pay $127.50 a share provided a negotiated deal can be reached, it said on Monday in a statement. The new offer is 2% more than Bayer’s previous bid and 19% above St. Louis-based Monsanto’s last closing price.

There’s no assurance an agreement will be reached, Bayer said. Monsanto said that it’s evaluating the Bayer offer as well as proposals from other parties and strategic alternatives.

The latest offer, which values Monsanto at about $56bn excluding debt, falls short of some predictions about what the company will have to pay to secure a takeover agreement. Analysts at Sanford C. Bernstein have previously said Monsanto may decide to sell if Bayer raises its offer to $135 a share.

Shares of Bayer slumped almost 0.8% to €94 as of 9:28 a.m. in Frankfurt trading. The stock has declined about 19% since the start of this year.

READ: Bayer could launch hostile bid for Monsanto: report

Bayer made its first offer of $122 a share in May. That was rejected by Monsanto as too low, as was the higher offer of $125 a share made in July, but Monsanto later granted its suitor some access to its financial accounts for the purposes of due diligence ahead of a potentially revised bid.

Monsanto’s shares have declined since Bayer’s initial bid in May, and closed at $107.44 in New York on Friday. There was no trading Monday because of the Labour Day holiday.

GMO pioneer

The offer from Bayer marks a reversal of roles for the US company. Monsanto has long sought to become a one-stop shop for farmers by boosting its crop chemicals portfolio to complement its seeds business. To that end, it had pursued the purchase of Syngenta on at least three separate occasions over the years.

The crop and seed industry is being reshaped by a series of large transactions that may end up leaving just a few global players who can offer a comprehensive range of products and services to farmers.

China National Chemical Corporation agreed in February to acquire Syngenta. Meanwhile, DuPont Company and Dow Chemical Company plan to merge and then carve out a new crop-science unit.

Global consolidation

Monsanto called off its Syngenta bid last year, while more recently it has revived talks to buy BASF’s agrochemicals unit. Falling crop prices have weighed on Monsanto’s profits and share price in the past year, making it vulnerable to a takeover.

Buying Monsanto would give Bayer a company that’s both the world’s largest seed supplier and a pioneer of crop biotechnology.

The kind of genetically modified seeds that Monsanto started to commercialize two decades ago now account for the majority of corn and soybeans grown in the US Monsanto also sells seeds in foreign markets including Latin America and India.

The company was founded in 1901 and its first product was saccharin, the artificial sweetener. It produced highly toxic polychlorinated biphenyls, known as PCBs, until the late 1970s, and was also among companies to manufacture the mixture of herbicides known as Agent Orange.

In the past two decades it has pioneered the commercialization of genetically modified organisms, or GMOs. GMO varieties of corn and soybeans now account for the majority of those crops in the US.

Read Fin24's top stories trending on Twitter:

ZAR/USD
17.60
(-1.63)
ZAR/GBP
23.20
(-2.09)
ZAR/EUR
20.85
(-1.45)
ZAR/AUD
12.65
(-1.46)
ZAR/JPY
0.17
(-1.67)
Gold
2047.55
(+0.59)
Silver
27.72
(+3.29)
Platinum
967.00
(+0.33)
Brent Crude
45.33
(+1.67)
Palladium
2195.00
(+0.96)
All Share
58073.68
(+0.77)
Top 40
53767.50
(+0.92)
Financial 15
9908.35
(-0.21)
Industrial 25
76753.06
(+0.78)
Resource 10
60644.39
(+1.43)
All JSE data delayed by at least 15 minutes morningstar logo
Company Snapshot
Voting Booth
Do you think it was a good idea for the government to approach the IMF for a $4.3 billion loan to fight Covid-19?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes. We need the money.
11% - 894 votes
It depends on how the funds are used.
74% - 5931 votes
No. We should have gotten the loan elsewhere.
15% - 1195 votes
Vote